Improvement of fatigue, depression, and processing speed two weeks post Natalizumab infusion in Multiple Sclerosis: No difference between standard and extended interval dosing schedules.
- DOI
- 10.1016/j.msard.2024.106146
- Published
- 2024-10-31
- Container
- Mult Scler Relat Disord
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.msard.2024.106146,
title = {Improvement of fatigue, depression, and processing speed two weeks post Natalizumab infusion in Multiple Sclerosis: No difference between standard and extended interval dosing schedules.},
author = {Leodori G and Mancuso M and Maccarrone D and Tartaglia M and Ianniello A and Baione V and Ferrazzano G and Malimpensa L and Belvisi D and Berardelli A and Pozzilli C and Conte A.},
year = {2024},
journal = {Mult Scler Relat Disord},
doi = {10.1016/j.msard.2024.106146},
url = {https://doi.org/10.1016/j.msard.2024.106146}
}RIS
TY - JOUR TI - Improvement of fatigue, depression, and processing speed two weeks post Natalizumab infusion in Multiple Sclerosis: No difference between standard and extended interval dosing schedules. AU - Leodori G AU - Mancuso M AU - Maccarrone D AU - Tartaglia M AU - Ianniello A AU - Baione V AU - Ferrazzano G AU - Malimpensa L AU - Belvisi D AU - Berardelli A AU - Pozzilli C AU - Conte A. PY - 2024 JO - Mult Scler Relat Disord DO - 10.1016/j.msard.2024.106146 UR - https://doi.org/10.1016/j.msard.2024.106146 ER -
APA
G, L., M, M., D, M., M, T., A, I., V, B., G, F., L, M., D, B., A, B., C, P., & A., C. (2024). Improvement of fatigue, depression, and processing speed two weeks post Natalizumab infusion in Multiple Sclerosis: No difference between standard and extended interval dosing schedules.. Mult Scler Relat Disord. https://doi.org/10.1016/j.msard.2024.106146
Source records
- europe-pmc · retrieved 2026-09-26T12:05:27.971Z